Richard Hawkins - Lumos Pharma CEO Chairman
Insider
Richard Hawkins is CEO Chairman of Lumos Pharma
| Age | 75 |
| Phone | 512 215 2630 |
| Web | https://lumos-pharma.com |
Lumos Pharma Management Efficiency
The company has return on total asset (ROA) of (0.6964) % which means that it has lost $0.6964 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7283) %, meaning that it created substantial loss on money invested by shareholders. Lumos Pharma's management efficiency ratios could be used to measure how well Lumos Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Lumos Pharma currently holds 585 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Lumos Pharma has a current ratio of 17.24, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Lumos Pharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Jonathan MD | Erasca Inc | 53 | |
| Conor Richardson | Shattuck Labs | N/A | |
| Andrew MBA | Shattuck Labs | 40 | |
| Michael Diem | Century Therapeutics | 53 | |
| Fatima MD | Shattuck Labs | N/A | |
| Brian MD | Rezolute | 50 | |
| David MD | Erasca Inc | 41 | |
| MD MBA | Rezolute | N/A | |
| Erin JD | Shattuck Labs | 44 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| BS CMAR | Champions Oncology | N/A | |
| Casi DeYoung | Shattuck Labs | 54 | |
| Shane Williams | Century Therapeutics | N/A | |
| Abhinav Shukla | Shattuck Labs | ||
| Kenneth Cundy | Anebulo Pharmaceuticals | 66 | |
| Michael MBA | Champions Oncology | N/A | |
| Steven Ruhl | Forte Biosciences | 68 | |
| Gregory Russotti | Century Therapeutics | 58 | |
| Chandra Lovejoy | Erasca Inc | 53 | |
| Mark Wallet | Century Therapeutics | N/A | |
| Daniel Ryweck | Silo Pharma | 59 | |
Management Performance
| Return On Equity | -1.73 | |||
| Return On Asset | -0.7 |
Lumos Pharma Leadership Team
Elected by the shareholders, the Lumos Pharma's board of directors comprises two types of representatives: Lumos Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lumos. The board's role is to monitor Lumos Pharma's management team and ensure that shareholders' interests are well served. Lumos Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lumos Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Hawkins, CEO Chairman | ||
| Lori CPA, CFO Officer | ||
| MD BA, Chief Officer | ||
| Lisa Miller, Director Relations | ||
| John McKew, Chief President | ||
| Bradley JD, Chief Counsel | ||
| Carl Langren, Consultant | ||
| BBA CPA, Chief Officer | ||
| MD FAAP, Chief Officer | ||
| Alpa Parikh, Senior Management | ||
| Eddie MBA, Corporate Controller |
Lumos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lumos Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.73 | |||
| Return On Asset | -0.7 | |||
| Operating Margin | (10.52) % | |||
| Current Valuation | 24.19 M | |||
| Shares Outstanding | 8.65 M | |||
| Shares Owned By Insiders | 32.69 % | |||
| Shares Owned By Institutions | 24.27 % | |||
| Number Of Shares Shorted | 54.33 K | |||
| Price To Earning | (2.37) X | |||
| Price To Book | 7.64 X |
Pair Trading with Lumos Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lumos Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lumos Pharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Alcoa Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alcoa Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alcoa Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alcoa Corp to buy it.
The correlation of Alcoa Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alcoa Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alcoa Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alcoa Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Lumos Stock
If you are still planning to invest in Lumos Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lumos Pharma's history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |